Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-Acetylcysteine (NAC) Treatment Clear all
Not listed Phase 4 Interventional

Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use

NCT03364218
View directory record Official record
Conditions
Bronchiolitis Acute
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
1 Week to 2 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional

A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease

NCT01800526
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Rifaximin With NAC in IBS-D

NCT04557215
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, N-acetylcysteine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 7, 2026, 4:32 AM EDT
Active, not recruiting Phase 1 Interventional

FIGHT-RP 1 Extension Study

NCT03999021
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
NAC effervescent tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

NCT00028262
View directory record Official record
Conditions
Infantile Neronal Ceroid Lipofuscinosis
Interventions
Cystagon
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 3 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

NCT02212678
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-acetylcysteine capsule
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 7, 2026, 4:32 AM EDT
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 7, 2026, 4:32 AM EDT
Enrolling by invitation Not applicable Interventional

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

NCT03032601
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
N-acetyl Cysteine
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 7, 2026, 4:32 AM EDT
Completed No phase listed Observational

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

NCT01465542
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

NCT00967005
View directory record Official record
Conditions
Gambling, Tobacco Use Disorder
Interventions
N Acetyl Cysteine, Sugar Pill
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

NCT01840345
View directory record Official record
Conditions
Neuropathic Pain
Interventions
N-acetyl-l-cysteine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Mucinex® for Treatment of Filamentary Keratitis

NCT02859246
View directory record Official record
Conditions
Filamentary Keratitis
Interventions
Mucinex®
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

NAC as a Potential Treatment for Methamphetamine Dependence

NCT01063205
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence, Substance Abuse
Interventions
Placebo, N-acetylcysteine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 7, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy

NCT03499249
View directory record Official record
Conditions
Biliary Atresia
Interventions
N-Acetyl cysteine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Days to 90 Days
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes

NCT02206152
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 7, 2026, 4:32 AM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

NCT03757585
View directory record Official record
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 7, 2026, 4:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

NCT03104725
View directory record Official record
Conditions
Parkinson Disease, Cerebrospinal Fluid
Interventions
N-Acetylcysteine, Lumbar Puncture, Fluoroscopy
Drug · Procedure · Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 7, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 7, 2026, 4:32 AM EDT